Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Alpibectir,Ethionamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : GSK
Deal Size : Undisclosed
Deal Type : Collaboration
BioVersys Expands Collaboration with GSK, Extending Series C Round by CHF 12.3 Million
Details : The collaboration with the GSK to accelerate the clinical development of BVL-GSK098 (alpibectir) for the treatment of tuberculosis.
Product Name : BVL-GSK098
Product Type : Antibiotic
Upfront Cash : Undisclosed
May 07, 2024
Lead Product(s) : Alpibectir,Ethionamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : GSK
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Alpibectir,Ethionamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : EDCTP
Deal Size : $2.8 million
Deal Type : Funding
BioVersys, TASK and GSK Receive 2.7 Million Euro from EDCTP for Phase 2a Clinical Trial
Details : The funding aims to advance the development of BVL-GSK098 (alpibectir) in combination withethionamide for treating Drug-Susceptible Pulmonary Tuberculosis in adult.
Product Name : BVL-GSK098
Product Type : Antibiotic
Upfront Cash : Undisclosed
February 25, 2021
Lead Product(s) : Alpibectir,Ethionamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : EDCTP
Deal Size : $2.8 million
Deal Type : Funding